MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
November 03, 2023 at 12:00 pm EDT
Share
MiNK Therapeutics, Inc. presented new agenT-797 data in solid tumor cancers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. Single administration of agenT-797 alone or in combination with anti-PD-1 delivered clinical benefit in heavily pre-treated patients with solid tumors: Phase 1 trial of agenT-797 alone or in combination with pembrolizumab or nivolumab without lymphodepletion (n=34) showed durable clinical benefit, including: Clinical response in MSI-high 3L gastric cancer patient after failure on pembrolizumab and nivolumab/FOLFOX; Long-term disease stabilization (n=10), including in testicular cancer (SD 9 months) and anti-PD-1 relapsed/refractory non-small-cell lung cancer (SD > 10 months); Tolerable safety profile with no dose-limiting toxicities and no grade >3 neurotoxicity or cytokine release syndrome. AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors: AgenT-797 was detected in the periphery for up to 6 months and persistence was independent of HLA matching; An increased level of immune cell tumor infiltration and neoantigen driven expansion of anti-tumor cytotoxic T cells was observed following administration; AgenT-797 promoted a systemic and local pro-inflammatory cytokine signature.
Expansion of clinical programs are underway in additional solid tumor settings, including relapsed/refractory gastric cancer: Expected launch of a randomized phase 2 trial in 2L gastric cancer, led by Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, by year-end 2023. The study will evaluate agenT-797 in combination with standard of care chemotherapy +/- Agenus? botensilimab/balstilimab combination; Expansion of phase 1 study underway to evaluate further signals in select tumor types, including non-small cell lung cancer and testicular cancer, and evaluate multi-dosing of agenT-797.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
MINK THERAPEUTICS, INC. 
